Perceptions of palliative care in Huntington's disease: A qualitative study.
Journal
Parkinsonism & related disorders
ISSN: 1873-5126
Titre abrégé: Parkinsonism Relat Disord
Pays: England
ID NLM: 9513583
Informations de publication
Date de publication:
Mar 2024
Mar 2024
Historique:
received:
14
11
2023
revised:
09
01
2024
accepted:
11
01
2024
pmc-release:
01
03
2025
medline:
26
2
2024
pubmed:
20
1
2024
entrez:
19
1
2024
Statut:
ppublish
Résumé
Palliative care focuses on improving patient and family quality of life by managing symptoms, psychosocial issues and spiritual concerns. Huntington's disease is a progressive neurodegenerative disorder with no current disease modifying therapy. Although the palliative care model has been postulated to be an integral part of HD care, there are gaps in knowledge about how this care should be implemented. This study aims to identify perceptions of palliative care in Huntington's Disease (HD), palliative care needs of people living with HD, and at what point they feel they would benefit from these resources. Participants volunteered from a large academic institution patient base to be involved in semi structured interviews that explored patient and caregiver experience surrounding their diagnosis, disease management, quality of life, and areas for improvement. Inclusion criteria for participants was a diagnosis of Huntington's disease and/or a self-identified caregiver of a person living with the disease. A total of 12 independent patients, three independent caregivers, and five dyads completed the interviews. Themes identified included needs that would provide patient and caregiver centered treatment, current gaps in care, an openness and desire for palliative care, and knowledge about the desired timing of palliative care in treatment plans. People living with HD and caregivers of people with HD most desire access to treatment that would focus on symptom management, availability of social resources, advanced care planning and spiritual wellbeing. The preferred timing of this intervention for most individuals would be at the onset of symptoms.
Identifiants
pubmed: 38241953
pii: S1353-8020(24)00019-1
doi: 10.1016/j.parkreldis.2024.106007
pmc: PMC10949181
mid: NIHMS1961131
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
106007Subventions
Organisme : NIA NIH HHS
ID : K02 AG062745
Pays : United States
Informations de copyright
Copyright © 2024 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Benzi Kluger reports financial support was provided by National Institute on Aging Laboratory of Neurosciences. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Drugs. 2017 Jan;77(1):29-46
pubmed: 27988871
Nurs Health Sci. 2004 Jun;6(2):123-30
pubmed: 15130098
Lancet Oncol. 2002 Mar;3(3):175-82
pubmed: 11902505
Curr Treat Options Oncol. 2020 Feb 5;21(2):12
pubmed: 32025964
Neurology. 2014 Aug 5;83(6):561-7
pubmed: 24991027
Mov Disord Clin Pract. 2018 Nov 16;6(2):125-131
pubmed: 30838311
Mayo Clin Proc. 2017 Oct;92(10):1592-1601
pubmed: 28982489
Neurology. 2021 Sep 7;97(10):e988-e995
pubmed: 34489348